These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 20439842)
1. Immunotherapy and multiple sclerosis: The devil is in the details. Bourdette D; Whitham R Neurology; 2010 May; 74(18):1410-1. PubMed ID: 20439842 [No Abstract] [Full Text] [Related]
2. Therapeutic role of mitoxantrone in multiple sclerosis. Neuhaus O; Kieseier BC; Hartung HP Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713 [TBL] [Abstract][Full Text] [Related]
4. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
5. A practical approach to immunomodulatory therapy for multiple sclerosis. Burks JS Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of mitoxantrone in multiple sclerosis--what is known? Neuhaus O; Kieseier BC; Hartung HP J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556 [TBL] [Abstract][Full Text] [Related]
9. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094 [TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone (Novantrone) in multiple sclerosis: new insights. Neuhaus O; Kieseier BC; Hartung HP Expert Rev Neurother; 2004 Jan; 4(1):17-26. PubMed ID: 15853611 [TBL] [Abstract][Full Text] [Related]
11. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889 [TBL] [Abstract][Full Text] [Related]
12. No shortcuts to outcome in MS clinical trials? Koch-Henriksen N Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696 [No Abstract] [Full Text] [Related]
13. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
15. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? Ellis R; Brown S; Boggild M Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152 [TBL] [Abstract][Full Text] [Related]
16. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis]. Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A; Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418 [TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Cocco E; Marchi P; Sardu C; Russo P; Paolillo A; Mascia M; Solla M; Frau J; Lorefice L; Massole S; Floris G; Marrosu M Mult Scler; 2007 Sep; 13(8):975-80. PubMed ID: 17468439 [TBL] [Abstract][Full Text] [Related]
18. Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis. Mattson DH Semin Neurol; 2002 Mar; 22(1):17-25. PubMed ID: 12170390 [TBL] [Abstract][Full Text] [Related]
19. Natalizumab for multiple sclerosis? Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381 [TBL] [Abstract][Full Text] [Related]
20. Rationale for the use of mitoxantrone in multiple sclerosis. Edan G; Morrissey S; Le Page E J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]